(Q37679880)

21 August 2017

1 reference

title

Mechanism of action of trazodone: a multifunctional drug (English)

1 reference

21 August 2017

1

Stephen M Stahl

1 reference

21 August 2017

publication date

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

536-546

1 reference

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Binding of antidepressants to human brain receptors: focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Multifunctional drugs as neurotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Modulation of dopamine release by striatal 5-HT2C receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Role of 5-HT(2C) receptors in the control of central dopamine function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

The sleep switch: hypothalamic control of sleep and wakefulness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

Multifunctional drugs: a novel concept for psychopharmacology

21 January 2018

2 references

https://api.crossref.org/works/10.1017%2FS1092852900024020

21 January 2018

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

Trazodone increases extracellular serotonin levels in the frontal cortex of rats

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

Pharmacokinetic and pharmacodynamic analyses of trazodone in rat striatum by in vivo microdialysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024020

7 January 2021

10.1017/S1092852900024020

Identifiers

DOI

1 reference

release_w5b3bh3pirhqvermgrrasey3eu

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/w5b3bh3pirhqvermgrrasey3eu

24 November 2022

mapped directly with Wikidata item

1 reference